MonumenTAL-8

A Phase 2, Open-Label, Multicenter Study of Ciltacabtagene Autoleucel and Talquetamab for the Treatment of Participants With High-Risk Multiple Myeloma

What's the purpose of the trial?

The purpose of this study is to define the safety of Ciltacabtagene Autoleucel (Cilta-cel) and Talquetamab in participants with high-risk multiple myeloma (MM).

Trial status

Not yet accepting

Phase

Phase 2

Enrollment

30

Last Updated

1 week ago

Participating Centers

There are 9 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

Ciltacabtagene Autoleucel (cilta-cel)
Daratumumab
Dexamethasone
Lenalidomide
Talquetamab

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Not yet accepting

Cohort 1: Cilta-cel + Talquetamab Consolidation Post Chimeric Antigen Receptor T cell (CAR-T)Therapy

Not yet accepting

Cohort 2: Cilta-cel + Talquetamab Consolidation Post CAR-T Therapy

Not yet accepting

Cohort 3: Tal Bridging Therapy Pre-CAR-T Therapy + Cilta-cel

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print this trial to share with your doctor.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.